|
| Press Releases |
|
 |
|
| Tuesday, December 1, 2020 |
|
|
BioVaxys Provides Viral Vaccine Platform Program Update |
| BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or "the Company") is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
| Monday, November 30, 2020 |
|
|
BioVaxys Provides Viral Vaccine Platform Program Update |
| BioVaxys Technology Corp. (CSE: BIOV) is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
| Wednesday, November 11, 2020 |
|
|
BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine |
| BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys") is pleased to announce that results from its preclinical animal study (also known as the "murine model study") of BVX-0320, its Covid-19 vaccine candidate, show that the vaccine elicits a positive immune response against the SARS-CoV-2 s-spike protein. more info >> |
|
| Monday, November 2, 2020 |
|
|
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity |
| BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or "the Company"), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
天數智芯推理业务大增238.2% 1000+项目验证 商業化加速落地
Apr 2, 2026 18:06 HKT/SGT
|
|
|
天数智芯推理业务大增238.2% 1000+项目验证 商业化加速落地
Apr 2, 2026 18:01 HKT/SGT
|
|
|
核心主業增長149.6% 推理業務大增238.2% 天數智芯2025年交出亮眼答卷
Apr 2, 2026 17:49 HKT/SGT
|
|
|
核心主业增长149.6% 推理业务大增238.2% 天数智芯2025年交出亮眼答卷
Apr 2, 2026 17:44 HKT/SGT
|
|
|
豪華新能源車企賽力斯營收破千億 高研發投入下的盈利與未來布局
Apr 2, 2026 17:20 HKT/SGT
|
|
|
豪华新能源车企赛力斯营收破千亿 高研发投入下的盈利与未来布局
Apr 2, 2026 17:14 HKT/SGT
|
|
|
國元國際：億勝生物科技拉開國際化序幕 維持「買入」評級 目標價6.84港元
Apr 2, 2026 17:03 HKT/SGT
|
|
|
国元国际：亿胜生物科技拉开国际化序幕 维持“买入”评级 目标价6.84港元
Apr 2, 2026 16:51 HKT/SGT
|
|
|
天數智芯通用GPU收入同比增長149.6% 推理系列大增238.2%
Apr 2, 2026 16:38 HKT/SGT
|
|
|
天数智芯通用GPU收入同比增长149.6% 推理系列大增238.2%
Apr 2, 2026 16:34 HKT/SGT
|
|
|
把握IPO回暖機遇 聯想控股戰略轉型邏輯逐步兌現
Apr 2, 2026 16:23 HKT/SGT
|
|
|
把握IPO回暖机遇 联想控股战略转型逻辑逐步兑现
Apr 2, 2026 16:17 HKT/SGT
|
|
|
Luxury NEV Enterprise Seres Hits Record High Revenue of RMB164.89 Billion in 2025, Maintaining Positive Profitability for Second Consecutive Year
Apr 2, 2026 16:09 HKT/SGT
|
|
|
Habitat for Humanity Asia-Pacific joins global 'Let's Open the Door' campaign to spotlight housing need
Apr 2, 2026 16:06 HKT/SGT
|
|
|
Driving Malaysia's Energy Transition: Solar & Storage Live Malaysia 2026 Returns to Kuala Lumpur
Apr 2, 2026 15:36 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
